Clinical Trial Risks and Benefits: What Every Diabetic Should Know

Why Clinical Trials Matter for Diabetes

Every diabetes treatment available today — from insulin analogs to continuous glucose monitors to GLP-1 receptor agonists — exists because thousands of patients volunteered to participate in clinical trials. As of 2025, diabetes research is advancing faster than at any point in history, with landmark trials like the Vertex VX-880 stem cell program, the PROTECT trial (teplizumab for early Type 1 diabetes), and multiple closed-loop insulin delivery studies actively enrolling participants or publishing results. Understanding how trials work — and what participation actually means for you — has never been more important.

The Four Phases of Clinical Trials: What They Mean

Clinical trials follow a structured four-phase process designed to protect participants while generating reliable data.

• Phase 1 — Small groups (20–80 people) test safety and dosing. These are the highest-risk trials, typically run in people who have exhausted other options or healthy volunteers.
• Phase 2 — Larger groups (100–300 people) test whether the treatment works and refine dosing. Some efficacy data emerges here.
• Phase 3 — Large-scale trials (1,000–3,000+ participants) compare the new treatment to existing standards of care. These are the pivotal trials that lead to FDA approval.
• Phase 4 — Post-market surveillance after FDA approval. These monitor long-term safety in the real world. The DEVOTE trial (insulin degludec cardiovascular outcomes) and LEADER trial (liraglutide) are famous Phase 4 examples that reshaped prescribing guidelines.

Real Risks You Should Understand

Clinical trials are not risk-free, and anyone who tells you otherwise is not being honest. Real risks include:

• Unknown side effects — Early-phase trials involve treatments with incomplete safety profiles. Vertex's VX-880 trial, for example, required participants to accept systemic immunosuppression to prevent rejection of implanted stem cell-derived islets — a serious long-term commitment.
• Placebo assignment — In blinded trials, you may receive a placebo rather than the experimental treatment. Ethical trial designs ensure placebo groups still receive standard-of-care diabetes management, but you may not receive the investigational drug.
• Time and logistical burden — Phase 2 and 3 trials often require frequent clinic visits, blood draws, continuous monitoring, and strict dietary or medication protocols that significantly impact daily life.
• Discontinuation — Trials can be stopped early due to safety signals, funding issues, or when interim data shows clear harm or clear benefit. Your treatment may change mid-study.
• Emotional risk — Hoping for a breakthrough and not achieving it is a real psychological burden many trial participants underreport.

Real Benefits That Are Equally Important

The benefits of trial participation are substantial and often undersold:

• Access to cutting-edge treatments — Patients in Vertex's VX-880 trial received investigational stem cell-derived islet cells years before any potential FDA approval, with some participants achieving meaningful insulin independence.
• Enhanced medical monitoring — Trial participants typically receive more frequent and comprehensive medical oversight than in standard care, catching complications earlier.
• No cost for trial-related care — Federal regulations require sponsors to cover all trial-related costs. Some trials also compensate for time and travel.
• Contributing to the future — The TrialNet natural history studies have enrolled over 200,000 relatives of people with Type 1 diabetes, generating data that directly shaped teplizumab's approval as the first disease-modifying therapy for T1D.

Current Status (2025)

The diabetes clinical trial landscape in 2025 is extraordinarily active. Key programs to know:

• Vertex Pharmaceuticals (VX-880 / VX-264) — VX-880, delivering stem cell-derived islet cells with immunosuppression, has shown promising early results. VX-264 encapsulates the same cells to potentially eliminate the need for immunosuppression. Both are in active trials.
• Teplizumab (Tzield, Provention Bio / Sanofi) — FDA-approved in 2022 for Stage 2 Type 1 diabetes after the PROTECT trial demonstrated delay of clinical T1D onset. Post-approval trials are ongoing to define optimal patient selection.
• Closed-loop insulin delivery — Multiple systems beyond the approved iLet Bionic Pancreas and Control-IQ are in trials, targeting fully automated glucose management with minimal user input.
• GLP-1 combinations in Type 1 — Trials combining GLP-1 agonists with insulin therapy in T1D are generating significant interest after observational data suggested weight and variability benefits.

Patients can search all active diabetes trials at ClinicalTrials.gov — the official U.S. registry — by condition, location, age, and phase.

What This Means for Patients

If you're managing diabetes today — whether relying on daily supplies available through resources like mdsdiabetes.com or navigating insurance challenges — a clinical trial might offer real value. But approach the decision carefully:

• Talk to your endocrinologist first — They can evaluate whether your current A1C, kidney function, cardiovascular status, and medication list make you a realistic candidate.
• Read the informed consent document completely — It must disclose all known risks. Ask questions until you fully understand every risk disclosed.
• Understand what you're giving up — Some trials require stopping current medications. Know exactly what your fallback care plan looks like.
• Ask about the sponsor — Industry-sponsored trials (like Vertex or Eli Lilly) have different incentive structures than NIH-funded academic trials. Neither is inherently better, but knowing who's funding helps you evaluate potential biases.

Honest Timeline Expectations

Even the most promising diabetes trials face long roads to patient access. Vertex's VX-880 program, despite exciting early results, is realistically a 5–8 year path to potential FDA approval assuming continued success. Teplizumab took over 20 years from initial concept to approval. Most Phase 2 trials never reach Phase 3. Temper your expectations accordingly — but don't let timelines stop you from contributing to science that will help future generations.